A relatively new treatment called CAR T-cell therapy appears to stop lupus in its tracks, according to a recent story by Nina Agrawal in The New York Times.
Her article explains that the treatment is "a kind of 'living drug' that modifies patients' immune cells to help them attack misbehaving ones."
Agrawal's piece quotes Dr. Lisa Sammaritano, a rheumatologist at the Hospital for Special Surgery — Weill Cornell Medicine and the lead author of a set of recently updated guidelines for lupus treatment, as saying, "It's really promising, and honestly the first therapy that we've talked about as a cure. [Until now] we haven't had a cure — we've had control."
She adds a major caveat, to the effect that she's "hoping that it's a common future therapy, but we're not at the point yet where we can say that with confidence."
CAR T-cell therapy, the Times story notes, is one that "must be personalized to each patient [and therefore] is extraordinarily expensive." One-time costs approach half a million dollars or more.
Symptoms of lupus typically appear between the ages of 15 and 44, with 90 percent of the 3 million patients worldwide being women.
![]() |
| Dr. Meghan Sise |
![]() |
| Dr. April Barnado |
It often strikes, she adds, "at a time when women are raising families, or they're caregiving, or they're trying to get promoted at work. They wake up and feel like they have the flu or a viral infection a few days a week every week. That's pretty debilitating."
Lupus, formally labeled systemic lupus erythematosus, according to the article "is an autoimmune condition in which he body develops antibodies against its own DNA and other cellular material. The name derives fro m the Latin for 'wolf,' because the skin lesions the disease sometimes causes were once thought to resemble wolf bites, some say."


No comments:
Post a Comment